Stay up-to-date with the latest news about Zuellig Pharma and the healthcare industry in Asia, as our experts from across the region share their insights.
Prioritising Patient Safety with Effective Digital Healthcare Management
Effective digital healthcare management ensures patient safety and accessibility. By prioritising patient-centric approaches and leveraging advanced technologies, healthcare organisations can optimise inventory management, reduce administrative burdens, and improve efficiency.
A Sustainable Approach to Healthcare Access Through Innovative Solutions
Zuellig Pharma is strengthening across all facets, building a resilient cross-regional supply chain, improving regional infrastructure, and sharing data and knowledge across markets, by leveraging technology and investing in sustainable practices.
Zuellig Pharma awarded EcoVadis Platinum Medal for fourth consecutive year, among top 60 companies worldwide
Zuellig Pharma over the past four years, has ranked within the top 1% of organisations worldwide, recognised for its performance in environmental efforts, labour and human rights, ethics and sustainable procurement.
With the global healthcare industry now responsible for 5 per cent of carbon emissions, more needs to be done to minimise waste especially in light of Asia's ageing population and increasing climate risks jeopardising health.
Zuellig Pharma enters into an agreement with Regeneron to bring Libtayo® (cemiplimab) to South Korea and Taiwan markets
Zuellig Pharma, a leading healthcare solutions company in Asia, has announced an exclusive distribution agreement with Regeneron Ireland DAC, a wholly owned subsidiary of Regeneron Pharmaceuticals, Inc. to launch and commercialise Libtayo (cemiplimab), a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells, in South Korea and Taiwan.
Interpharma Investments Limited appoints multidisciplinary healthcare leader Christiane Hamacher as new board director
Interpharma Investments Limited, the holding company of leading healthcare solutions provider Zuellig Pharma, today announced the appointment of Dr. Christiane Hamacher as a new member of its Board of Directors.
Zuellig Pharma Partners Novartis to Expand Access of Strategic Portfolio of In-Market Brands in Singapore
Zuellig Pharma Singapore will leverage our deep-rooted expertise and proven track record in the healthcare market in Asia, to serve as Novartis Singapore's dedicated commercialisation and distribution partner across medical oncology, neuroscience and general medicine.
Effective digital healthcare management ensures patient safety and accessibility. By prioritising patient-centric approaches and leveraging advanced technologies, healthcare organisations can optimise inventory management, reduce administrative burdens, and improve efficiency.
Zuellig Pharma is strengthening across all facets, building a resilient cross-regional supply chain, improving regional infrastructure, and sharing data and knowledge across markets, by leveraging technology and investing in sustainable practices.
Zuellig Pharma over the past four years, has ranked within the top 1% of organisations worldwide, recognised for its performance in environmental efforts, labour and human rights, ethics and sustainable procurement.
With the global healthcare industry now responsible for 5 per cent of carbon emissions, more needs to be done to minimise waste especially in light of Asia's ageing population and increasing climate risks jeopardising health.
Zuellig Pharma, a leading healthcare solutions company in Asia, has announced an exclusive distribution agreement with Regeneron Ireland DAC, a wholly owned subsidiary of Regeneron Pharmaceuticals, Inc. to launch and commercialise Libtayo (cemiplimab), a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells, in South Korea and Taiwan.
Interpharma Investments Limited, the holding company of leading healthcare solutions provider Zuellig Pharma, today announced the appointment of Dr. Christiane Hamacher as a new member of its Board of Directors.
Zuellig Pharma Singapore will leverage our deep-rooted expertise and proven track record in the healthcare market in Asia, to serve as Novartis Singapore's dedicated commercialisation and distribution partner across medical oncology, neuroscience and general medicine.
New agreement marks major milestone for Zuellig Pharma as it focuses on expanding its consumer healthcare segment, and for Institut AllergoSan as it expands its global presence.
Ensuring a resilient, digitised supply chain is crucial for the healthcare industry to manage complexities, prevent drug spoilage, and maintain patient access to high-quality treatments and clinical trials.
New platform provides quick, easy and a streamlined digital purchasing process for orders, payments and returns of prescription drugs, medical devices or consumer health products anytime, anywhere.
Zuellig Pharma will be the exclusive commercialisation partner for Karo's over-the-counter (OTC) brand Lamisil, a product for the treatment of fungal infections, across Hong Kong, Malaysia, Philippines, Singapore, South Korea, Taiwan and Vietnam.
This collaboration signifies a pivotal milestone in advancing healthcare infrastructure in Laos. By leveraging the expertise and resources of both organisations, the partnership aims to address critical healthcare challenges, particularly in underserved regions, and improve the overall quality of healthcare services available to the people of Laos, aligning with the key objectives of the Ministry of Health of Laos PDR.
With evolving patient needs, emerging disease areas and new innovations driving this fast-moving landscape, we need to collectively prioritise access to healthcare, affordability and sustainability to benefit the health of communities across Asia.
The acquisition of Cialis and Alimta marks a major milestone in the evolution of Zuellig Pharma to becoming an integrated healthcare solutions company. It demonstrates the increasing strength of ZP Therapeutics, which has extensive in-market expertise and capabilities in driving growth of healthcare products in Asia.
The US-ASEAN Business Council has spearheaded efforts that highlight regional gaps and opportunities across individual sectors such as biopharma and healthcare.
Zuellig Pharma, a leading healthcare solutions company, has been appointed as the exclusive distribution partner of STADA Philippines Inc., a fast-growing supplier of high-quality pharmaceuticals and an affiliate of Germany's STADA Arzneimittel AG.
Zuellig Pharma, Asia’s leading healthcare solutions company, has recently signed a new strategic partnership with ACEN Renewable Energy Solutions (ACEN RES), the retail electricity arm of ACEN, to supply 100% renewable energy to power two major distribution facilities in the Philippines – the Santa Rosa Distribution Center and Canlubang Distribution Center.
Zuellig Pharma, a leading healthcare solutions company in Asia, has announced that it has achieved the platinum medal from EcoVadis, the world’s most trusted provider of business sustainability ratings, for the third consecutive year.
Zuellig Pharma, one of the largest healthcare services groups in Asia, today announced that it has entered into an agreement with global biopharma company, GSK, to help set up its first vaccine.
Interpharma Investments Limited (IIL), holding company of leading healthcare solutions company Zuellig Pharma, is pleased to announce the appointment of Mr. Shai Ganu as a new member of the IIL Board of Directors effective 1 November 2023.
Interpharma Investments Limited, holding company of leading healthcare services provider Zuellig Pharma, today announced the appointment of Mr. Alfonso “Chito” Zulueta as Non-Executive Chairman of its Board. Effective 1 June 2023, Mr. Zulueta succeeds Mr. Patrick Davies, who stepped down after serving as Non-Executive Chairman for four years.
Zuellig Pharma, one of the largest healthcare services groups in Asia, has announced its score of “A-” for Supplier Engagement from global carbon disclosure platform CDP, making it the first and only company worldwide in its activity group to receive this recognition.
The World Health Organization officially declared the coronavirus outbreak a pandemic in March 2020. By June 2021, 170 vaccine candidates for COVID-19 had been developed. Of these, 90 were being tested in human clinical trials, 30% had reached Phase 3 and selected vaccines had been authorised for emergency use. There are at least 440 clinical trials with mRNA candidates and at least 140 for viral vectors.
ZP Therapeutics is ready to deliver the first shipment of 560,000 doses of COVID-19 Vaccine Moderna to the Government Pharmaceutical Organisation (GPO) for distribution to the Private Hospital Association in an effort to increase access to alternative vaccines for the people of Thailand.
Zuellig Pharma announced a new partnership with GW Pharmaceuticals (GW) to support access to cannabis-based medicines in Taiwan. GW, part of Jazz Pharmaceuticals plc, is a world leader in discovering, developing, and delivering regulatory approved cannabis-based medicines.
ZP Therapeutics, a division of Zuellig Pharma and the official partner of Moderna in Thailand, confirms that the first shipment of 560,000 doses of COVID-19 Vaccine Moderna will arrive in Thailand within 5 November 2021, based on the latest schedule provided by Moderna.
Zuellig Pharma has been appointed by the Department of Disease Control to handle and distribute another 20 million doses of the Pfizer-BioNTech COVID-19 vaccines in Thailand.
Technology like smartphones, laptops and smartwatches have blurred the lines between work and personal time even before the COVID-19 pandemic hit us almost two years ago.
The award is the highest accolade to be awarded to a company for its sustainability efforts and positions Zuellig Pharma in the top 1% of all assessed companies worldwide.
The Chulabhorn Royal Academy (CRA) announced an official agreement with ZP Therapeutics, a division of Zuellig Pharma on the supply and distribution of eight million doses of the COVID-19 Vaccine Moderna in Thailand.
ZP Therapeutics, a division of Zuellig Pharma today announced that Thailand Food and Drug Administration (FDA) has expanded the authorisation of the COVID-19 Vaccine Moderna for use in adolescents aged 12 to 17 years old.
Zuellig Pharma, a leading healthcare services provider in Asia, has been presented with four leadership and sustainability awards, in both individual and enterprise categories, at the recent Asia Corporate Excellence and Sustainability (ACES) Awards. Organised by MORS Group, the annual ACES Awards is a prestigious accolade that recognises inspiring leaders, sustainability advocates as well as businesses' contributions to their communities and the world.
Zuellig Pharma is committed to leveraging our experience, expertise and our best in class cold chain solutions for distribution of vaccines, pharmaceutical and medical products to provide access to COVID-19 vaccines to the people in Thailand.
Zuellig Pharma is working with Chulalongkorn University to develop ChulaCov19, Southeast Asia's first COVID-19 mRNA vaccine. As part of the ChulaCov19 mRNA vaccine programme, Zuellig Pharma managed the clinical trials, which included storing and distributing the vaccines to clinical sites.
ZP Therapeutics, a division of Zuellig Pharma, today announced an official agreement with the Government Pharmaceutical Organisation (GPO) to supply and distribute five million doses of the COVID-19 Vaccine Moderna in Thailand from the fourth quarter of 2021.
Zuellig Pharma Corporation was authorised by Moderna as the emergency use authorisation holder (through its commercialisation division, ZP Therapeutics) for its COVID-19 vaccine in the Philippines.
Zuellig Pharma marked the week from 24 to 30 April 2021 with a series of events to engage employees on the topic of immunisation. This included a company-wide survey to understand if employees had concerns about vaccination and what these concerns stem from.
Held in conjunction with the WHO’s World Immunisation Week 2021, the landmark event saw experts across various fields coming together to lead exciting discussions on innovative ways to roll out vaccines in Asia
Zuellig Pharma and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines announced a new partnership with Zuellig Pharma’s division, ZP Therapeutics, to supply the COVID-19 Vaccine Moderna in Southeast Asia, Hong Kong, Macau and Taiwan.
Zuellig Pharma today announced that it has scooped two titles at the Asia-Pacific Bioprocessing Excellence Awards 2021. The company clinched awards for ‘Best Warehousing & Distribution’ and ‘Best Last Mile Implementation’ for a second year running.
The COVID-19 pandemic defence has entered a new phase since the start of 2021 with vaccine supplies slowly beginning to arrive in countries across the globe, as part of the internationally funded COVAX programme or through direct purchases by country governments from manufacturers.
Zuellig Pharma today announced the launch of eZVax, a vaccine management solution that enables governments and private clients to manage all aspects of vaccine distribution and administration.
The United Nations marked a milestone 75th anniversary last year, with a call to focus on global cooperation in building the future we want. I believe the world has made some headway with shaping this future, particularly with the launch of the Sustainable Development Goals in 2016.
In a year marked by a pandemic and continued global uncertainty, 32 companies across Singapore have been named among HR Asia’s Best Companies to Work for in Asia.
To help governments, pharmaceutical companies and healthcare providers combat the trade in fake medicines, Zuellig Pharma launched eZTracker in the region earlier this year.
Filipino doctors are conducting much fewer consultations since the COVID-19 health crisis in March this year, according to a recent survey conducted by a team of researchers from Zuellig Pharma.
Zuellig Pharma has signed a partnership agreement with Celltrion, a Korean leading biopharmaceutical group to distribute Regkirona (Regdanvimab) for COVID-19 patients in Korea.
COVID-19 has underscored the critical role that safety plays in businesses. As Asia's leading healthcare services provider, over 350,000 hospitals, clinics and medical centres rely on Zuellig Pharma to deliver healthcare products.
Zuellig Pharma has launched eZConsult, a virtual care mobile app to address the growing need for teleconsultation amidst lockdowns and restricted movement during the global COVID-19 pandemic.
Zuellig Pharma in response to the impact on the healthcare landscape, have witnessed their teams across all 13 markets and business units come together in exceptional ways to make healthcare accessible to the communities they serve.
Zuellig Pharma announces the appointment of John Graham as its new CEO. John will run the US$13 billion business and lead the team across our 13 markets in Asia.
The COVID-19 has had far-reaching effects on global supply chains. Supply chains all over the world have been put to the test as countries and businesses battle to effectively manage disruptions caused by the pandemic.
Zuellig Pharma enters a partnership agreement with Luye Pharma Group, an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications.
This International Women’s Day, we interview three outstanding female colleagues from our Distribution & Client Services team. Hear from Natalie Guo, Ngo Hong Mai and Imelda Leslie V. Rillon as they share about their role models and advice for women in healthcare.
The COVID-19 outbreak has seen more than 1,800 infected patients in nearly all provinces within Thailand. This aims to support the country in its fight against the virus.
Zuellig Pharma announced that it has joined the Poseidon integrated pharmaceutical ocean freight network as the principal distribution partner in Asia Pacific. It is also one of the latest members to be part of this network of more than 30 pharma companies and logistics providers which comprise the global Poseidon cold-chain reform project
This International Women’s Day, we interview three outstanding female colleagues from our CareConnect team. Hear from Lily Lan, Karen Goh and Sirena Loh as they share about what motivates them, their female role models and words of wisdom for women in the healthcare industry.
Zuellig Pharma, a leading healthcare services provider in Asia, has announced that it has acquired a controlling stake in Alliance Pharma (Cambodge), a leading healthcare distributor of Cambodia.
Zuellig Pharma has announced the launch of eZTracker in Thailand and partnered with global pharmaceutical company, Galderma (Thailand) Ltd to help consumers identify unauthorized aesthetics products
As part of their commitment to increase healthcare access in Indonesia, PT Anugerah Pharmindo Lestari (APL) officially introduced its new state-of-the-art National Distribution Centre (NDC), located in West Java, Indonesia, on 3 February 2020.
Leading healthcare services provider Zuellig Pharma has received a Silver medal from sustainability rating specialist EcoVadis for its commitment to driving sustainability within its business.
As part of the partnership with the National Institute for Control of Vaccines and Biologicals (NICVB) and the National Institute of Hygiene and Epidemiology (NIHE) to improve access to vaccination in Vietnam, Zuellig Pharma Vietnam organised an event to handover US$600,000 worth of the eZCooler solution on 20 December 2019.
The Philippine Academy of Family Physicians (PAFP) will collaborate with telemedicine app eZConsult as the digital platform for its remote consultation initiative dubbed Family and Community Engagement through Telehealth Service (FACETS)
Zuellig Pharma, a leading healthcare service provider in Asia, is pleased to announce two new strategic partnerships with Eli Lilly and Company (Lilly) to market, sell and distribute the healthcare manufacturer's existing and new products in Malaysia and Thailand.
<span style="background-color: #ffffff; color: #000000;">The commercialisation of Granulox and Granudacyn in South-East Asia was previously managed by SastoMed’s exclusive strategic partner, Zuellig Pharma, one of Asia’s largest healthcare services provider.</span>
Zuellig Pharma has acquired Singapore-based Healthtech start-up Klinify, to support the development of technology that empowers doctors to modernise their practices and simplify workflows. Klinify is a cloud-based digital medical assistant used by over 800 doctors in Malaysia to manage their clinics more efficiently.
Under the agreement, Zuellig Pharma will contribute hundreds of the innovative eZCooler solution, a temperature-controlled packaging technology to maintain product quality during transportation.
Many organisations struggle with consolidating and translating the wealth of data they have into actionable insights because the data sits in segregated silos. These silos stem from the need to comply with strict data privacy policies and laws, resulting in various clinical, financial and operational data being housed separately.
.webp)
.webp)
.jpeg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
